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AbstrAct
clinical rationale for the study. Neurological deficits and progressing disability in patients with multiple sclerosis (MS) may 
hamper daily oral hygiene, but their relations with oral problems have not yet been clearly determined. 
Aim of the study. The aim of this study was to identify the most significant dental problems and limitations of daily oral hygiene 
in Polish patients with MS.
Material and methods. 199 patients with diagnosed MS (median age 37 years) treated in the neurological outpatient clinic 
were interviewed using a paper-based questionnaire. They provided answers on oral health, behaviours and the limitations of 
their daily oral hygiene. Clinical information regarding symptoms, MS phenotype, relapses, medication and degrees of disability 
was based on medical records.
results. The most frequent symptoms were dry mouth (43.2%) and bleeding from gums (28.1%). Dry mouth was more frequ-
ent in patients with secondary-progressive MS (SPMS) than relapsing-remitting MS (65.4% vs 41.3%, p = 0.023). Patients with 
bleeding from gums had had MS for a longer duration (median 6 vs 4 years, p = 0.002). Difficulties in daily oral hygiene were 
more frequent in patients with SPMS (24.0% vs 8.1%; p = 0.016). Greater proportions of patients with muscle weakness of limbs, 
imbalance or pain brushed their teeth irregularly. Frequent (i.e. at least every six months) visits to the dentist’s surgery were 
uncommon in patients with SPMS (12.0% vs 39.7%, p = 0.010).
conclusions and clinical implications. Dry mouth and bleeding from gums are more frequent in patients with longer lasting 
and more advanced types of MS. Daily oral hygiene and oral health self-control is limited in patients with MS, mainly due to 
motor deficits, balance problems and pain, and this becomes worse with disease duration.
To minimise the burden of the disease, patients with MS require better education and improvement in their awareness regar-
ding proper oral health control, such as the use of electric toothbrushes. In addition, patients with chronic and progressive 
disability from multiple sclerosis may benefit from better organised access to dental care.
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Introduction
Multiple sclerosis (MS) is a chronic, inflammatory, demy-
elinating and neurodegenerative disease of the central nervous 
system (CNS), which damages myelin sheaths, oligodendro-
cytes, as well as nerve cells and axons. It is characterised by 
gradual and progressive limitation of functional abilities, 
consequently leading to disability. The first symptoms of the 
disease usually appear between the ages of 20 and 40 years, 
and therefore MS is considered the most common cause of 
disability in younger people [1].
Individual clinical presentations, and the rate of accumula-
tion of disability, may be different in each patient and depend 
on the location and the amount of demyelinating lesions in 
the CNS. Clinical symptoms of MS include, but are not limi-
ted to, motor deficits, sensory disturbances, visual disorders, 
bulbar symptoms, cognitive dysfunction, dysautonomia and 
mental disorders [2–8], which individually or in combinations 
may hamper oral hygiene. Progressive functional disability 
and medication used for the treatment of MS may also be 
associated with greater incidences of oral diseases and dental 
problems [9–13].
Daily oral hygiene, frequency of visits to the dentist’s sur-
gery, and mouth discomfort have been identified as the main 
dental problems requiring medical attention in patients with 
MS [9–15]. To date, there has been no study of oral problems 
or difficulties in oral hygiene in patients with MS in Poland. 
Therefore, the purpose of this study was to identify the most 
significant limitations of daily oral hygiene in Polish patients 
with MS, to assess the incidence and type of dental problems, 
and to evaluate their association with clinical features, as well 
as social and economic factors.
Material and methods
Consecutive subjects were recruited among patients with 
MS diagnosed according to the 2010 McDonald criteria [16], 
who were treated in the Neurological Outpatient Clinic at 
the Department of Neurology of Medical University of Silesia 
(Zabrze) between 1 July 2014 and 31 January 2015. The study 
was conducted according to the principles of the Declaration 
of Helsinki and all participants provided written informed 
consent. The protocol of the study was reviewed and approved 
by Ethics Committee of our institution.
Each patient was interviewed using a questionnaire de-
vised by ourselves, and provided answers to several general 
and specific questions. General questions concerned age, sex, 
education, professional activity, familial status, course of the 
disease (age of first symptoms and diagnosis, phenotype of 
MS, current symptoms, number and frequency of relapses 
during the disease course, previous and current medication) 
and comorbidities. Clinical information about relapses, 
medication and disability degree measured with Expanded 
Disability Status Scale (EDSS) [17] was verified with the 
outpatient’s neurological documentation. Specific questions 
concerning dental health status and dental care included: 
frequency of visits to the dentist’s surgery, time since the last 
visit, behaviours and habits of oral hygiene, problems with 
daily oral hygiene, oral sensations, preferences for specific 
foods or drinks, and history of smoking. 
Statistical analysis was performed using STATISTICA 
12 software (Stat Soft, Poland) and R 3.3.2 (GNU General 
Public License). Data were presented as means with standard 
deviation (± SD), median with minimum and maximum va-
lues or as percentages. After checking for normality with the 
Shapiro-Wilk test, to analyse the between-groups differences 
Student’s t-test or Mann-Whitney U test were used and chi-
-square or Fisher’s exact tests were used for categorical data. 
A p value < 0.05 was considered significant.
Results
The study included 199 patients (143 women; 71.9%) with 
diagnosed MS (median age 37 years, range 18–67 years) and 
with a median duration of 4 years (range 0–27 years) since 
diagnosis. Socioeconomic and clinical data of the studied 
group are given in Table 1. In general, patients with secondary 
progressive MS (SPMS) were older than those with the re-
lapsing-remitting form of MS (RRMS) (median age 48.5 years, 
29–67 years vs 36 years, 18–65 years, respectively; p < 0.001) 
and on average had had the disease for longer (median 6 years 
from diagnosis, 1–24 years, vs 4 years, 1–27 years, respectively), 
but this difference was not statistically significant (p = 0.076).
Oral and dental problems
Dry mouth and bleeding from gums were the most 
frequent symptoms reported by 86 (43.2%) and 56 (28.1%) 
patients with MS, respectively. The incidence of oral and 
dental problems, limitations and behaviours of oral hygiene 
is summarised in Table 2. The most frequent symptoms (dry 
mouth and bleeding from gums) were not related to the age of 
the patient (p = 0.392 and p = 0.877, respectively). However, 
the incidence of dry mouth was higher in patients with SPMS 
than in patients with RRMS (65.4% vs 41.3%, respectively; p 
= 0.023). The incidence of bleeding from gums was not dif-
ferent between patients with SPMS or RRMS (p = 0.873), but 
patients with bleeding from gums had had their disease for 
longer than patients without (median 6 years, 0–27 years, vs 
4 years, 0–24 years, respectively; p = 0.002). 
There was no difference in the incidence of dry mouth and 
bleeding from gums between patients using Disease Modifying 
Drugs (DMD) or not (p = 0.994 and p = 0.662, respectively), 
nor they were associated with the use of any specific DMD 
(p = 0.230 and p = 0.363, respectively). Dry mouth was more 
frequent in patients who reported that they had received at 
least one course of steroids in the past (50.0% vs 31.3%; p = 
0.013). On the other hand, it was not associated with any type 
of symptomatic treatment for MS, in which dry mouth may 
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table 1. Socioeconomic and clinical data of 199 patients with multiple sclerosis (MS)
Patients; n (%)
Education
Elementary
Secondary
High
Undergraduate
4 (2.0)
68 (34.2)
90 (45.2)
36 (18.1)
Professionally active 116 (58.3)
Number of children
0
1
2
> 3
77 (38.7)
58 (29.2)
56 (28.1)
8 (4.0)
Marital status
Single
Married or in partnership
75 (37.7)
124 (62.3)
Economic status (income)
Above high
High 
Average
Low
14 (7.0)
93 (46.3)
89 (44.7)
2 (1.0)
Phenotype of Ms
Relapsing-remitting MS
Secondary progressive MS
No data
151 (75.9)
26 (13.1)
22 (11.0)
EDSS score (mean ± SD) 3.2 + 1.9
Number of relapses per year (mean ± SD) 1.3 + 0.9
Time from last relapse; months (mean ± SD) 21.5 + 23.7
reported symptoms of Ms
Muscle weakness in at least one limb
Sensory disturbances
Balance problems
143 (71.9)
134 (67.3)
111 (55.8)
Pain (different localisations) 54 (27.0)
Patients; n (%)
Visual disturbances 13 (6.5)
Fatigue 4 (2.0)
Disease Modifying Drugs (DMD) received
Interferon beta
Glatiramer acetate
Fingolimod
Natalizumab 
No DMD
No data
112 (56.3)
19 (9.5)
19 (9.5)
4 (2.0)
37 (18.7)
8 (4.0)
Methylprednisolone (at least once in a lifetime) 92 (46.2)
Main symptomatic Ms treatment  
(indication)
Myorelaxants (spasticity)
Antiepileptic drugs (sensory disturbances )
Amantadine (fatigue)
Oxybutynin (urine urgency)
9 (4.5)
8 (4.0)
4 (2.0)
3 (1.5)
comorbidities
Thyroid disease
Arterial hypertension
Coronary artery disease 
Chronic urinary tract infection
Mental disorders
Liver diseases
Diabetes mellitus
27 (13.7)
25 (12.6)
5 (2.5)
4 (2.0)
4 (2.0)
4 (2.0)
2 (1.0)
Oral contraceptives (women only) 4 (2.8)
Active cigarette smokers 55 (28)
Alcohol consumption
Regular
At least once a week
124 (62.3)
8 (4%)
Note: Unless otherwise indicated, presented data are numbers of patients in the studied group 
(with respective percentages given in brackets). SD – standard deviation; EDSS – Expanded 
Disability Status Scale
be one of the side effects (mainly myorelaxants, antiepileptic 
drugs, amantadine, oxybutynin, oral contraceptives or antide-
pressants) (p = 0.127). Bleeding from gums was not associated 
with steroid use or any concomitant medication (p = 0.660).
Daily oral hygiene
Difficulties with daily oral hygiene were reported more of-
ten by patients with SPMS than by patients with RRMS (24.0% 
vs 8.1%; p = 0.016). Patients with selected neurological focal 
deficits related to MS also more frequently reported difficul-
ties with daily oral hygiene than did patients without them: 
1) muscle weakness of limbs (23.4% vs 5.8%, respectively; 
p < 0.001); 2) imbalance (27.3% vs 6.8%, respectively; p < 
0.001); and 3) pain (25.0% vs 8.9%, respectively; p = 0.030). 
Additionally, insufficient brushing of the teeth – once a day or 
less – was significantly more frequent in patients with muscle 
weakness of limbs, imbalance or pain, than in those without 
these specific symptoms – two or three times per day (29.8% 
vs 15.0%, p = 0.007; 33.3% vs 15.0%, p = 0.029 and 35.0% vs 
16.4%, p = 0.046, respectively). Patients with bleeding from 
gums less often used an electric toothbrush (8.9% vs 22.5%; p 
= 0.028) and brushed their teeth less frequently, but this diffe-
rence was not significant (p = 0.067). Reported problems with 
oral hygiene were not associated with gender, age, education, 
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table 2. Oral problems, behaviours and limitations of oral hygiene repor-
ted by 199 patients with multiple sclerosis (MS). Data presented as n (%)
Patients; n (%)
Oral and dental problems
Dry mouth 
Bleeding from gums
Metallic flavour in the mouth 
Dysgeusia 
Pain during brushing the teeth 
Burning in the mouth 
86 (43.2)
56 (28.1)
21 (10.6)
20 (10.1)
10 (5.0)
8 (4.0)
Difficulties in daily oral hygiene
Minor 
Moderate 
Help from another person 
No data
17 (8.5)
4 (2.0)
1 (0.5)
4 (2.0)
brushing of teeth
Three or more times a day 
Twice a day
Once a day
Occasionally
No data
34 (17.1)
123 (61.8)
36 (18.1)
2 (1.0)
4 (2.0)
toothbrush used
Traditional
Electric
No data
159 (79.9)
36 (18.1)
4 (2.0)
Additional behaviours of oral hygiene
Mouth fluid
Dental floss
Irrigator
84 (42.2)
79 (39.7)
3 (1.5)
Visits to the dentist’s office
Every six months
Once a year
Less than once a year
Only in an emergency
No data 
69 (34.7)
68 (34.2)
30 (15.1)
26 (13.1)
6 (3.0)
Last visit to the dentist
Less than six months ago
Between six and 12 months ago
More than 12 months ago
No data
49 (24.6)
79 (39.7)
39 (19.6)
32 (16.1)
Fear of dentists 56 (28.1)
Nutritional preferences (regular consumption)
Sparkling water
Meat
Vitamin supplements 
Fruit juices
Flour products
Sweet drinks
Sweets
Sweets in the evening after teeth brushing
Still water
137 (68.8)
134 (67.3)
120 (60.3)
90 (45.2)
81 (40.7)
29 (40.6)
76 (38.2)
52 (26.1)
48 (24.1)
professional activity, marital, familial and economic status, 
degree of disability (EDSS), comorbidities, used MS therapy 
or mean number of relapses per year.
Oral health self-control
Regular (at least every six months) visits to the dentist’s sur-
gery were reported by a greater proportion of patients with 
RRMS than those with SPMS (39.7% vs 12.0%), and therefore 
a greater proportion of patients with SPMS visited the dentist 
less frequently than patients with RRMS (52.0% vs 33.6% at least 
once a year and 28.0% vs 11.6% less than once a year, respectively; 
p = 0.010). Women and patients with a better level of education 
visited the dentist’s more often than others (p = 0.010 and p = 
0.001, respectively). The frequency of visits was not associated 
with age, professional activity, marital, familial and social status, 
degree of disability, reported symptoms, concomitant diseases, 
type of therapy used or the  annual number of relapses. 
Discussion
In the presented study, the main reasons for oral discom-
fort in Polish patients with MS were xerostomia (43.2%) and 
gingival bleeding (28.1%). The prevalence of xerostomia in the 
general population ranges significantly, from 0.9% to 64.8% 
[18], depending on the population studied and the methodology 
used. In our study, the frequency of xerostomia in patents with 
MS was considered high, because our patients were on average 
younger than the overall general population, and problems with 
a dry mouth are usually more prevalent among the elderly [19].
Dry mouth was more frequent in patients with the se-
condary progressive MS phenotype and those who had used 
steroids in the past. In our opinion, this is less likely to be 
a specific side effect of steroids use and more likely to be part 
of this type of MS, because patients with SPMS are older, 
have had their disease for longer, have more neurological 
symptoms, and there is a higher chance that they were treated 
with steroids in the past [20]. It is possible that dysautono-
mia and sensory disturbances in long-lasting MS may be the 
cause of xerostomia in these patients, but such a hypothesis 
requires further investigation. On the other hand, steroids 
are recommended in the treatment of Sjögren’s syndrome, an 
autoimmune disease in which the main symptoms are dry eyes 
and mouth, so a short course of steroids (even repeated) can 
be beneficial for xerostomia [21]. 
Dry mouth was not associated with the use of DMD, nor 
with any specific medication. This is consistent with the general 
risk profile of most newer-generation DMDs – e.g. interferons, 
glatiramer acetate, fingolimod or natalizumab – compounds 
that were used in our patients. Against this, teriflunomide has 
been reported to raise the risk of tooth loss [22], but none of 
our patients was receiving this treatment. Medication used in 
the symptomatic management of MS may have the potential 
to cause dry mouth and other oral diseases [9, 13]. Individu-
al patients in our group were taking baclofen, amantadine, 
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oxybutynin or contraceptive drugs, but the overall incidence of 
xerostomia was not higher, probably because of the significant 
heterogeneity of the group and only single patients receiving 
such treatment. Tobacco use is often the cause of dry mouth 
[23], but in the studied group the proportion of active cigarette 
smokers was comparable to that in the general population.
Bleeding from gums was reported by less than 28.1% of pa-
tients with MS, compared to a 50% incidence of gingival bleeding 
in healthy Poles [24]. The average age of responders in that study 
was higher, by more than a dozen years, than in our group and 
gingival bleeding was largely related to the fact of brushing the 
teeth and the type of toothbrush bristles (soft, medium, hard). 
In our group, patients with bleeding from gums significantly less 
often brushed their teeth using an electric toothbrush (2.5 times 
less frequently), therefore a manual toothbrush could be the one 
of the risk factors for gingival bleeding. In other populations of 
patients with MS, this incidence of gingival bleeding has been 
estimated as being 5–15% [12, 25]. This difference could be 
the result of a different methodology of acquisition of data, as 
we questioned patients about any possible incident of gingival 
bleeding, whereas in other studies this symptom could be actually 
confirmed during an intraoral examination.
Substantial difficulties and limitations of daily oral hygiene 
were reported by about 11% of patients with MS, and they 
were three times more frequent in patients with SPMS than 
in RRMS (24% vs 8%). Patients with SPMS may have more 
severe neurological deficits and higher degrees of disability 
to interfere with oral hygiene and access to dental services 
[20]. We identified weakness of limbs, imbalance and pain 
to be the main factors limiting daily oral hygiene. In other 
studies in patients with MS, visual disturbances, facial pain, 
trigeminal neuralgia, paresthesia, spasticity, spasms, tremor, 
fatigue and depression have also been found [9, 13], but our 
group consisted of younger participants and with a shorter 
disease duration than the general population of patients with 
MS, therefore with less disease-related burden.
Oral hygiene in patients with MS rarely attracts the atten-
tion of neurologists, but dental problems should be expected 
and explored, particularly because of the chronic character of 
the disease and the progressive disability of patients. In our 
study, 61.8% of patients with MS said that they brushed their 
teeth twice a day, which is a higher proportion than estima-
ted in the general Polish population (54.7%) [26]. A similar 
proportion was observed in a British population of patients 
with MS (66%), although this was less often than in the gene-
ral population in the UK (74%) [27]. Individual neurological 
deficits reported by studied patients, mainly weakness of limbs, 
imbalance and pain, were significant factors contributing to 
irregular (once a day or less) brushing of the teeth.
Additional aids can help in maintaining proper oral health 
in individuals with significant neurological deficits. Unfor-
tunately, in the studied group a hygiene fluid was used less 
frequently (42.2%) than in healthy Poles (67%), as was dental 
floss (39.7% vs 57%) [26]. Electric brushes can reduce plaque 
by 7–57.9%, gingival inflammation by 17–19.8%, and bleeding 
of gingiva by 85.2%, and they are more effective compared 
to manual brushes [28]. In our study, almost 80% of patients 
with MS used manual toothbrushes (in this group was more 
gingival bleeding), which is 13% more than in the general 
Polish population. Neurologists should educate patients about 
proper oral hygiene, because immunosuppressive therapy or 
corticosteroids may additionally raise the risk of oral infections 
in patients with MS [29].
Active participation of individuals in dental health self-
-control was significantly limited in our patients with MS. Only 
24.6% of patients reported that they had visited the dentist 
within the last six months, compared to 56% of adult healthy 
Poles [26]. Patients with SPMS visited dentists significantly 
less frequently than patients with RRMS, therefore functional 
disability could be one of the reasons for worse oral health self-
-care. However, we suspect that not only neurological deficits 
were responsible, because in the comparable group in the UK, 
81% of MS patients and 71% of non-MS subjects claimed to 
visit the dentist at least once a year [27], which was reported 
only by 34.2% patients from the studied group. This means 
that dental care in Poland is less available, probably because 
of architectonical barriers, insufficient awareness of healthy 
behaviours or anxiety regarding the dentist. This finding was 
surprising, because patients with MS in our study were younger 
than the overall population with MS and so would be expected 
to be more proactive in such behaviours. 
The advantage of the presented study is the quite large 
studied group and clinical data verification with clinical neu-
rological documentation. However, limitations to the study 
are one-time observation and the collection of data only 
by questionnaire and without a dentist’s visual evaluation. 
Enrolled patients were younger than the general population, 
younger than the general population of patients with MS, and 
with a shorter disease duration. We see this study as a preli-
minary report. Research will be continued, especially in older 
MS patients, and also in those with primary progressive MS.
Conclusions and clinical implications
Patients with MS may complain about similar conditions 
causing oral discomfort as healthy individuals, such as dry 
mouth and bleeding from gums, but these symptoms are more 
frequent and more pronounced in patients with longer lasting 
and more advanced types of the disease. Daily oral hygiene, as 
well as regular oral health self-control, is substantially limited 
in patients with MS, mainly due to motor deficits, balance 
problems and pain, and this becomes worse with disease dura-
tion. To minimise the burden of the disease, patients with MS 
require better education and improved awareness about proper 
oral health control, such as the use of electric toothbrushes. 
In addition, patients with chronic and progressive disability 
from multiple sclerosis may benefit from better organised 
access to dental care.
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